
# Darunavir/r in Treatment-Experienced Children and Adolescents **DELPHI Trial**



## Darunavir/r in Treatment-Experienced Children and Adolescents DELPHI: Study Design

#### Study Design: DELPHI

- Background: Open-label, phase 2 trial evaluating the pharmacokinetics, safety, and efficacy of darunavir + ritonavir + OBR in treatment-experienced children/adolescents with HIV infection
- Inclusion Criteria (Part I: n=44, Part II: n=80)
  - Age 6 to 17, treatment-experienced
  - Body weight ≥20 kg
  - HIV RNA >1000 copies/mL
  - Stable CD4%
- Treatment Arms
  - Group A (weight-based): DRV 9-15 mg/kg + RTV 1.5-2.5 mg/kg bid + OBR\*
  - Group B (higher dose): DRV 11-19 mg/kg + RTV 1.5-2.5 mg/kg bid + OBR\*




**DELPHI** =  $\underline{\mathbf{D}}$ arunavir  $\underline{\mathbf{E}}$ va $\underline{\mathbf{L}}$ uation in  $\underline{\mathbf{P}}$ ediatric,  $\underline{\mathbf{H}}$ IV- $\underline{\mathbf{I}}$ nfected, treatment-experienced patients \*Optimized background regimen =  $\geq 2$  active antiretroviral agents (NRTIs, EFV, NVP, or ENF)



### Darunavir/r in Treatment-Experienced Children and Adolescents DELPHI: Result

#### Week 4: Virologic Response (ITT Analysis)






Source: Blanche S, et al. AIDS. 2009;23:2005-13.

### Darunavir/r in Treatment-Experienced Children and Adolescents DELPHI: Result

Week 48: Virologic Response (TLOVR)





Source: Blanche S, et al. AIDS. 2009;23:2005-13.

### Darunavir/r in Treatment-Experienced Children and Adolescents DELPHI: Conclusions

**Conclusion**: "In treatment-experienced children and adolescents, DRV/r showed comparable exposure to adults with appropriate dose selection, favorable safety and tolerability, improved body weight and significant virologic response. DRV/r is a valuable therapeutic option for this population."



### Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.



